Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant zanidatamab + tislelizumab + gemcitabine/cisplatin for bladder preservation in HER2-positive MIBC
ChiCTR2500110562Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanidatamab, tislelizumab, cisplatin and gemcitabine in muscle-invasive urothelial bladder carcinoma (MIBC), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Clinical complete response rate (cCR rate). Planned start Oct 2025; status: not yet recruiting.
02
Drugs
zanidatamabtislelizumabcisplatingemcitabine
03
Conditions
muscle-invasive urothelial bladder carcinoma (MIBC)
Beyond the preview
Go deeper on ChiCTR2500110562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110562.